ViCentra, the European medical device company behind the Kaleido insulin patch pump, has successfully secured an additional $13 million in its Series D financing round. This latest investment brings the total capital raised to an impressive $98 million, underscoring strong investor confidence in the company's vision. The funds are earmarked to scale manufacturing, expand European commercial operations, and accelerate preparations for entry into the U.S. market.
Bolstering Investor Confidence and Market Strategy
The second closing of the round introduces new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech. This follows an initial $85 million raised in September 2025 and includes increased support from existing backer Innovation Industries. The sustained financial backing validates ViCentra’s strategic direction and significant operational progress over the past year.
ViCentra's momentum is evidenced by a remarkable year in which it doubled its user base to over 4,000 people, driving substantial revenue growth. This strong adoption in key markets like Germany, the Netherlands, and France has established a solid foundation for its ambitious expansion plans. The company's performance has been a key factor in attracting this follow-on investment for its next phase of growth.
Innovating Insulin Delivery with User-Centric Design
At the heart of ViCentra's success is the Kaleido system, recognized as the smallest and lightest insulin patch pump available. It offers precise, automated insulin delivery through its integration with Diabeloop’s clinically validated DBLG1 and DBLG2 hybrid closed-loop algorithms. This technology is designed to simplify daily diabetes management and provide users with greater therapeutic control.
Distinguishing itself from competitors, Kaleido is designed to feel more like personal technology than a conventional medical device. Users can personalize their pump with interchangeable aluminum shells available in ten vibrant colors, reflecting individual style. This user-centric approach, blending medical precision with thoughtful design, aims to empower users and improve their quality of life.
Accelerating Growth and Future Ambitions
With the new capital, ViCentra will focus on scaling its manufacturing capabilities to meet rapidly growing demand across Europe. The company plans to deepen its commercial execution and support infrastructure in Germany, the world's second-largest insulin pump market, as well as in France and the Netherlands. This expansion is central to its goal of nearly tripling its European user community by the end of 2026.
Looking ahead, a significant portion of the funding will accelerate preparations for launching a next-generation Kaleido system in the United States. CEO Tom Arnold emphasized the company's commitment to converting high demand into satisfied users through uncompromising quality and performance. This strategic move into the U.S. market represents a pivotal step in ViCentra's global growth strategy.
This successful $98 million Series D financing round marks a transformative milestone for ViCentra, equipping it with the resources for significant expansion. The investment will fuel the company's growth in key European markets while paving the way for a strategic U.S. launch. Ultimately, ViCentra is now better positioned than ever to advance its mission of making diabetes management simpler and more personalized through innovative technology.